According to the above studies, EGFR protein positivity is observed in the vast majority of NSCLC tumour specimens (ranging from approximately 70 to 90% in most studies), which makes this marker unlikely to be used in practice for patient selection. The gene discussed is EGFR; the disease is neoplasm.